Job Opportunities

Human Resources Manager

As Human Resources Manager, you will provide H.R. support to a dynamic and growing team.  The opportunity is in Foster City, California and reports to the Vice President, Human Resources.  The successful candidate will be an accomplished H.R. generalist.  In addition to being a Business Partner, this position will provide support in a number of H.R. functional areas including talent acquisition, learning & development, total rewards, and H.R. Information Management.  This is an exciting hands-on opportunity to join a growing team – and a great opportunity to join a company with an inspiring mission in the oncology space.

Primary Responsibilities:

  • Talent Acquisition: Manage full recruitment life cycle including position definition, job postings, candidate screening, interviewing and recommending top talent, coordinating with hiring managers and their teams, final candidate selection, candidate close, and onboarding.
  • Lead H.R. Initiatives: These include lead in the selection and implementation of a companywide LMS, updating H.R. information retention systems, and ensuring HR policies align with industry best practices
  • Performance Management: Assist in goal alignment and performance feedback systems
  • Total Rewards: Aid in benchmarking compensation competitiveness and in communicating company’s excellent benefits programs
  • Fun: Be key player in instigating and planning fun

Qualifications:

  • Bachelor’s Degree with a minimum of five years Human Resources experience
  • Excellent verbal and written communications skills
  • Experience in recruiting life cycle, including assessing talent
  • Experience in biotech preferred
  • Experience with TriNet platform preferred
  • Be a fun and energetic contributor to Apollomics culture

Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies that harness the immune system and target specific molecular pathways to eradicate cancer globally. The company’s existing pipeline consists of five development-stage assets including two novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and three targeted therapies against uncontrolled growth signaling pathways.